Survival Impact of Adjuvant Therapy in Salivary Gland Cancers following Resection and Neck Dissection

Show simple item record Aro, Katri Ho, Allen S. Luu, Michael Kim, Sungjin Tighiouart, Mourad Yoshida, Emi J. Mallen-St Clair, Jon Shiao, Stephen L. Leivo, Ilmo Zumsteg, Zachary S. 2020-08-31T01:51:14Z 2021-12-18T03:45:59Z 2019-06
dc.identifier.citation Aro , K , Ho , A S , Luu , M , Kim , S , Tighiouart , M , Yoshida , E J , Mallen-St Clair , J , Shiao , S L , Leivo , I & Zumsteg , Z S 2019 , ' Survival Impact of Adjuvant Therapy in Salivary Gland Cancers following Resection and Neck Dissection ' , Otolaryngology - Head and Neck Surgery , vol. 160 , no. 6 , pp. 1048-1057 .
dc.identifier.other PURE: 126209299
dc.identifier.other PURE UUID: c878c72c-837a-4d54-8b92-330eba42bf8e
dc.identifier.other WOS: 000470767300014
dc.description.abstract Objective To evaluate the impact of postoperative radiotherapy (PORT) and chemotherapy on survival in salivary gland cancer (SGC) treated with curative-intent local resection and neck dissection. Study Design Retrospective population-based cohort study. Setting National Cancer Database. Subjects and Methods Patients with SGC who were undergoing surgery were identified from the National Cancer Database between 2004 and 2013. Neck dissection removing a minimum of 10 lymph nodes was required. Because PORT violated the proportional hazards assumption, this variable was treated as a time-dependent covariate. Results Overall, 4145 cases met inclusion criteria (median follow-up, 54 months). PORT was associated with improved overall survival in multivariable analysis, both 9 months (HR, 0.75; 95% CI, 0.66-0.86; P <.001). In propensity score-matched cohorts, 5-year overall survival was 67.1% and 60.6% with PORT and observation, respectively (P <.001). Similar results were observed in landmark analysis of patients surviving at least 6 months following diagnosis. Adjuvant chemotherapy was not associated with improved survival (HR, 1.15; 95% CI, 0.99-1.34; P = .06). Conclusion PORT, but not chemotherapy, is associated with improved survival among patients with SGC for whom neck dissection was deemed necessary. These results are not applicable to low-risk SGCs not requiring neck dissection. en
dc.format.extent 10
dc.language.iso eng
dc.relation.ispartof Otolaryngology - Head and Neck Surgery
dc.rights.uri info:eu-repo/semantics/openAccess
dc.subject salivary gland cancer
dc.subject metastasis
dc.subject radiotherapy
dc.subject survival
dc.subject CARCINOMA
dc.subject SURGERY
dc.subject HEAD
dc.subject IRRADIATION
dc.subject IMPUTATION
dc.subject 3125 Otorhinolaryngology, ophthalmology
dc.subject 3126 Surgery, anesthesiology, intensive care, radiology
dc.title Survival Impact of Adjuvant Therapy in Salivary Gland Cancers following Resection and Neck Dissection en
dc.type Article
dc.contributor.organization HUS Head and Neck Center
dc.contributor.organization Korva-, nenä- ja kurkkutautien klinikka
dc.description.reviewstatus Peer reviewed
dc.relation.issn 0194-5998
dc.rights.accesslevel openAccess
dc.type.version publishedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
0194599819827851.pdf 1.592Mb PDF View/Open

This item appears in the following Collection(s)

Show simple item record